Calliditas Announces Positive Data From Proof-of-concept Phase 2 Trial With Setanaxib
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Calliditas Therapeutics (CALT) reported data from the proof-of-concept Phase 2 trial evaluating setanaxib, the company’s lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and neck. The analysis showed st
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2076671053-ff0e800c89684fabb96eb46d32650e55.jpg "Why and How Student Loan Creditors Can Garnish Your Money")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-510752465-10cdb9eac0884220ae04232d2950ca87.jpg "This Is the Perfect Place for Your Second Home Abroad—And It Might Not Be Where You Think")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1567505009-09f8705bfdcd40aaa9797052677728ba.jpg "Using the Coppock Curve to Generate Trade Signals")
:max_bytes(150000):strip_icc():format(jpeg)/Familyusinglaptopathome-151c2ebff99c4ca380c4db33a9c6c97a.jpg "Using an Inherited IRA to Buy a House")